Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Lim M, et al. Among authors: sahebjam s. Neuro Oncol. 2022 Nov 2;24(11):1935-1949. doi: 10.1093/neuonc/noac116. Neuro Oncol. 2022. PMID: 35511454 Free PMC article. Clinical Trial.
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Ellingson BM, et al. Among authors: sahebjam s. Neuro Oncol. 2017 Jan;19(1):89-98. doi: 10.1093/neuonc/now187. Epub 2016 Aug 31. Neuro Oncol. 2017. PMID: 27580889 Free PMC article. Clinical Trial.
Progression pattern and adverse events with bevacizumab in glioblastoma.
Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, Sharma R, Kavan P. Mamo A, et al. Among authors: sahebjam s. Curr Oncol. 2016 Oct;23(5):e468-e471. doi: 10.3747/co.23.3108. Epub 2016 Oct 25. Curr Oncol. 2016. PMID: 27803607 Free PMC article.
Immunotherapy and radiation in glioblastoma.
Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Sahebjam S, et al. J Neurooncol. 2017 Sep;134(3):531-539. doi: 10.1007/s11060-017-2413-0. Epub 2017 May 31. J Neurooncol. 2017. PMID: 28567588 Review.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Omuro A, et al. Among authors: sahebjam s. Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208. Neuro Oncol. 2018. PMID: 29106665 Free PMC article. Clinical Trial.
Barriers to accrual and enrollment in brain tumor trials.
Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY. Lee EQ, et al. Among authors: sahebjam s. Neuro Oncol. 2019 Sep 6;21(9):1100-1117. doi: 10.1093/neuonc/noz104. Neuro Oncol. 2019. PMID: 31175826 Free PMC article. Review.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Lee EQ, et al. Among authors: sahebjam s. Neuro Oncol. 2020 May 15;22(5):601-612. doi: 10.1093/neuonc/noaa015. Neuro Oncol. 2020. PMID: 31974566 Free PMC article.
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Reardon DA, et al. Among authors: sahebjam s. JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024. JAMA Oncol. 2020. PMID: 32437507 Free PMC article. Clinical Trial.
75 results